Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cholinergic systems in progressive supranuclear palsy.

N M Warren1, M A Piggott, E K Perry

  • 1Institute for Ageing and Health, University of Newcastle upon Tyne, UK. n.m.warren@ncl.ac.uk

Brain : a Journal of Neurology
|January 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trajectories of pain over 6 years in early Parkinson's disease: ICICLE-PD.

Journal of neurology·2021
Same author

Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson's Disease Cohort (ICICLE-PD).

Brain sciences·2020
Same author

Prevalence and duration of non-motor symptoms in prodromal Parkinson's disease.

European journal of neurology·2019
Same author

A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2018
Same author

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study.

Journal of neurology, neurosurgery, and psychiatry·2017
Same author

Cognitive impairment in Parkinson's disease: impact on quality of life of carers.

International journal of geriatric psychiatry·2016
Same journal

The significance of electrophysiological recordings from the bed nucleus of the stria terminalis in humans.

Brain : a journal of neurology·2026
Same journal

Fus-depleted oligodendrocytes reduce neuronal damage and Alzheimer's disease progression in the AppNL-G-F mouse.

Brain : a journal of neurology·2026
Same journal

Cervical lymph node biomarkers in neurodegeneration.

Brain : a journal of neurology·2026
Same journal

Lower motor neuron disorders: time for a closer look.

Brain : a journal of neurology·2026
Same journal

Reply: Cervical lymph node biomarkers in neurodegeneration.

Brain : a journal of neurology·2026
Same journal

Propionic acid and neurofilament light chain in multiple sclerosis.

Brain : a journal of neurology·2026
See all related articles

Progressive supranuclear palsy (PSP) involves cholinergic deficits impacting motor and cognitive functions. Understanding cholinergic receptor status is crucial for improving treatments for this neurodegenerative disease.

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Background:

  • Progressive supranuclear palsy (PSP) is a neurodegenerative disease characterized by motor, cognitive, and gaze impairments.
  • Pathological hallmarks include tau protein accumulation and damage to cortico-basal ganglia loops.
  • Cholinergic deficits are implicated in PSP's postural instability and cognitive decline, yet current treatments show limited efficacy.

Purpose of the Study:

  • To review the clinical features of PSP.
  • To discuss basal ganglia anatomy and cholinergic transmission.
  • To explore cholinergic deficits in PSP and suggest future therapeutic directions.

Main Methods:

  • Review of clinical and neurochemical parameters related to PSP.
  • Examination of basal ganglia anatomy and cholinergic pathways.

Related Experiment Videos

  • Analysis of existing literature on cholinergic deficits and treatments in PSP.

    • Main Results:

    • Cholinergic dysfunction in PSP is linked to neuronal loss in the striatum and reduced input from key cholinergic nuclei.
    • While cholinergic neuron loss is evident, the status of muscarinic and nicotinic receptors remains unknown.
    • This lack of knowledge may explain the limited success of current cholinomimetic therapies.

    Conclusions:

    • Targeting specific cholinergic receptors or nuclei may enhance symptomatic treatment efficacy in PSP.
    • Further research into cholinergic receptor status is vital for developing improved therapeutic strategies.
    • Cholinergic agents may possess disease-modifying potential in progressive supranuclear palsy.